Eli Lilly and Company (LLY)
Market Movers: 2 Top Dividend Stocks I'm Watching No Matter Who Wins
With the upcoming election sparking volatility, I'm sharing two dividend stocks on my radar. These picks offer reliable growth potential, no matter the political outcome. Each stock has a solid track record of outperformance and strong fundamentals. I'm confident they could deliver stability and compound over time, even through uncertainty. Adding these to my watch list reflects my belief in their resilience and potential. These are stocks I'd consider buying soon, regardless of the election's impact.
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
The market overreacted to Lilly's Q3 earnings miss and full-year guidance cut.
Eli Lilly viewed positively despite Mounjaro, Zepbound disappointment - BoA
Bank of America has stuck by Eli Lilly and Co (NYSE:LLY) despite underwhelming sales of its weight loss and diabetes products Zepbound and Mounjaro in the third quarter. Reiterating a ‘buy' rating, Bank of America noted it remained “positive” on Eli “on weakening manufacturing headwinds and acceleration of on-demand activities”.
Eli Lilly Earnings Have Wall Street Jittery on Zepbound Sales. What Comes Next.
Sales of Zepbound and Mounjaro both missed Wall Street estimates by significant margin.
Buy, Sell, Or Hold LLY Stock At $850?
Eli Lilly stock (NYSE: LLY) fell over 6% on Wednesday, October 30, after it posted downbeat results. The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below the consensus estimates of $12.1 billion and $1.45, respectively.
Are Eli Lilly's Lowered Expectations a Reason to Sell?
Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024.
Eli Lilly and Company (LLY) Q3 2024 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY ) Q3 2024 Earnings Conference Call October 30, 2024 10:00 AM ET Company Participants Joe Fletcher - Senior Vice President-Investor Relations Dave Ricks - Chief Executive Officer Lucas Montarc - Chief Scientific Officer and President, Lilly Immunology Gordon Brooks - Group VP, Controller and Corporate Strategy and Interim CFO Dan Skovronsky - Chief Scientific Officer and President-Lilly Immunology Patrik Jonsson - President-Lilly Diabetes and Obesity and Lilly USA Ilya Yuffa - Executive Vice President Jacob Van Naarden - President, Lilly Oncology Conference Call Participants Chris Schott - JPMorgan Geoff Meacham - Citigroup Evan Seigerman - BMO Capital Seamus Fernandez - Guggenheim Mohit Bansal - Wells Fargo Terence Flynn - Morgan Stanley Umer Raffat - Evercore ISI Steve Scala - TD Cowen David Risinger - Leerink Kerry Holford - Berenberg Chris Shibutani - Goldman Sachs Trung Huynh - UBS Courtney Breen - Bernstein Operator Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I would now like to turn the conference over to your host, Joe Fletcher, Senior Vice President of Investor Relations.
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.1% on Wednesday.
What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment
Eli Lilly's eyewatering upsurge this year was upended by its double-slashed full-year 2024 guidance following the Q3 earnings update this morning. The slight Q3 revenue miss continues to highlight volatile supply chain dynamics facing its best-selling Zepbound/Mounjaro tirzepatide products. Investors were also caught off guard by the unprecedentedly material acquired IPR&D charge related to LLY's acquisition of Morphic Holdings in Q3.
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.S. The drugmaker blamed the misses on drug wholesalers cutting inventory of Zepbound and Mounjaro.
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates.
Eli Lilly: The Stock Might Have Peaked
Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was a great investment — mostly due to the success of Mounjaro and Zepbound. Nevertheless, the stock seems expensive — also when compared to Novo Nordisk — and we should be very cautious about an investment.
